Figure 3.

(A) VEGF, (B) MCP-1, and (C) CXCL10 secreted protein levels in ARPE-19 cell culture supernatants in normal glucose (5.5 mM) and high glucose (30 mM) conditions, following treatment with bevacizumab (0.3 mg/mL), triamcinolone (1 mg/mL), and their combination (0.3 mg/mL + 1 mg/mL) for 48 hours. Data are shown as mean $\pm$ SEM of three independent biological replicates. Statistical significance was assessed using one-way ANOVA with Tukey's post-hoc test: P $\le$ 0.05 (*), P $\le$ 0.01 (**), P $\le$ 0.001 (***). M, mannitol osmotic control; C, control; B, bevacizumab; T, triamcinolone; BT, combination.